CONDENSED UNAUDITED INTERIM STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock	Additional Paid-in Capital	Subscription Receivable	Accumulated Deficit
Balance at Dec. 31, 2023	$ 35,635,609	$ 1,441	$ 61,501,801	$ (11,250)	$ (25,856,383)
Beginning balance, shares at Dec. 31, 2023		14,405,325
Stock-based compensation expense	435,663		435,663
Exercise of stock options	1,975		1,975
Exercise of stock options (in shares)		1,829
Exercise of warrants	1,360,457	$ 21	1,509,686	(149,250)
Exercise of warrants (in shares)		206,018
Proceeds from subscription receivable	11,250			11,250
Net Income (Loss)	(5,051,913)				(5,051,913)
Balance at Mar. 31, 2024	32,393,041	$ 1,462	63,449,125	(149,250)	(30,908,296)
Ending balance, shares at Mar. 31, 2024		14,613,172
Balance at Dec. 31, 2023	35,635,609	$ 1,441	61,501,801	(11,250)	(25,856,383)
Beginning balance, shares at Dec. 31, 2023		14,405,325
Net Income (Loss)	(11,965,011)
Balance at Sep. 30, 2024	32,010,188	$ 1,523	69,830,059		(37,821,394)
Ending balance, shares at Sep. 30, 2024		15,221,308
Balance at Mar. 31, 2024	32,393,041	$ 1,462	63,449,125	(149,250)	(30,908,296)
Beginning balance, shares at Mar. 31, 2024		14,613,172
Stock-based compensation expense and vesting of restricted stock units	662,321	$ 1	662,320
Stock-based compensation expense and vesting of restricted stock units (in shares)		5,000
Sale of common stock , net of issuance costs	4,943,668	$ 60	4,943,608
Sale of common stock , net of issuance costs (in shares)		603,136
Proceeds from subscription receivable	149,250			149,250
Net Income (Loss)	(2,891,680)				(2,891,680)
Balance at Jun. 30, 2024	35,256,600	$ 1,523	69,055,053	$ 0	(33,799,976)
Ending balance, shares at Jun. 30, 2024		15,221,308
Stock-based compensation expense	775,006		775,006
Net Income (Loss)	(4,021,418)				(4,021,418)
Balance at Sep. 30, 2024	32,010,188	$ 1,523	69,830,059		(37,821,394)
Ending balance, shares at Sep. 30, 2024		15,221,308
Balance at Dec. 31, 2024	39,577,095	$ 1,671	80,312,594		(40,737,170)
Beginning balance, shares at Dec. 31, 2024		16,707,441
Stock-based compensation expense	1,080,082		1,080,082
Exercise of stock options	19,137	$ 2	19,135
Exercise of stock options (in shares)		17,557
Net Income (Loss)	(7,306,757)				(7,306,757)
Balance at Mar. 31, 2025	33,369,557	$ 1,673	81,411,811		(48,043,927)
Ending balance, shares at Mar. 31, 2025		16,724,998
Balance at Dec. 31, 2024	$ 39,577,095	$ 1,671	80,312,594		(40,737,170)
Beginning balance, shares at Dec. 31, 2024		16,707,441
Exercise of stock options (in shares)	35,114
Net Income (Loss)	$ (15,517,565)
Balance at Sep. 30, 2025	27,284,491	$ 1,675	83,537,551		(56,254,735)
Ending balance, shares at Sep. 30, 2025		16,742,638
Balance at Mar. 31, 2025	33,369,557	$ 1,673	81,411,811		(48,043,927)
Beginning balance, shares at Mar. 31, 2025		16,724,998
Stock-based compensation expense	1,035,713		1,035,713
Net Income (Loss)	(6,094,977)				(6,094,977)
Balance at Jun. 30, 2025	28,310,293	$ 1,673	82,447,524		(54,138,904)
Ending balance, shares at Jun. 30, 2025		16,724,998
Stock-based compensation expense	1,070,892		1,070,892
Exercise of stock options	19,137	$ 2	19,135
Exercise of stock options (in shares)		17,557
Exercise of warrants (in shares)		83
Net Income (Loss)	(2,115,831)				(2,115,831)
Balance at Sep. 30, 2025	$ 27,284,491	$ 1,675	$ 83,537,551		$ (56,254,735)
Ending balance, shares at Sep. 30, 2025		16,742,638

Coya Therapeutics, Inc. 10-Q